Why 'not yet' is a clinically defensible position

A knee OA diagnosis does not come with a fixed deadline. Knee replacement is an elective procedure, and its timing is a shared decision between patient and clinician — shaped by symptom severity, functional loss, and what matters most to the person living with the joint, not by a biological countdown triggered the moment wear is confirmed on imaging.

Choosing not to proceed with replacement yet is not the same as doing nothing. Between an OA diagnosis and a surgical decision sits a substantial, evidence-backed treatment pathway — layered across lifestyle modification, injection options, and, for appropriate candidates, joint-preserving surgery. Each tier has a body of clinical evidence behind it, and the sequence in which interventions are applied tends to matter: earlier action generally produces better outcomes, which is why this is a moment to begin structured management rather than wait for symptoms to worsen.

What follows maps that pathway in practical terms — starting with the options carrying the strongest evidence, working through injectable treatments, and finishing with the surgical alternatives that can meaningfully defer or, in some cases, avoid full replacement altogether.

Exercise: the one intervention with the highest-grade evidence

Structured land-based exercise holds a status no other knee OA treatment currently matches. The OARSI guidelines — the most widely cited international framework for non-surgical OA management — place it in the 'Core Treatment' tier, meaning the evidence is strong enough, and consistent enough, to recommend it for virtually every person with knee OA regardless of other factors. No injection, no supplement, and no device shares that designation.

The scale of the evidence behind that label is considerable. A cumulative meta-analysis drawing on 42 randomised controlled trials and 6,863 patients confirms exercise reduces pain and functional impairment — and critically, that finding has been stable since 2010. Researchers analysing the literature concluded that further trials are unlikely to change the conclusion: this is settled science.

The most practically important finding for anyone diagnosed now comes from a 2024 individual patient data meta-analysis of 1,767 participants across ten RCTs. People who began exercise with a symptom history of one year or less showed a mean pain reduction 8.33 points greater (on a 100-point scale; 95% CI −12.51 to −4.15) at around twelve months than those with a longer symptom history. Put plainly: there is a window of opportunity, and starting exercise earlier sits within it.

Why exercise works remains genuinely unclear. Knee extension strength accounts for roughly 2% of the benefit; range of motion and proprioception account for none — leaving around 98% of the effect mechanistically unexplained. That uncertainty does not weaken the clinical case; it simply means the prescription does not need to be built around a single physical target.

In practice, the best programme is the one a person will actually follow. Evidence now confirms that remote and digital delivery achieves equivalent outcomes to in-person supervision, which broadens access considerably. The specific format — resistance, aerobic, aquatic, or a combination — is best matched to the individual rather than prescribed uniformly.

Weight loss: meaningful only above a threshold

Most people assume that losing any amount of weight will ease their knee pain. The evidence is more specific. A 2024 network meta-analysis drawing on 13 randomised controlled trials and 2,800 overweight or obese adults with knee OA found that meaningful pain relief was associated with losing at least 7% of body weight. Below that figure, the signal is unreliable; above it, the benefit becomes clinically significant.

Reaching that threshold requires more than one approach working in isolation. The same analysis identified a combination of dietary change, structured exercise, and psychological support as the most effective strategy — no single component reliably delivered the required loss on its own.

For those wondering why this helps beyond the obvious mechanical explanation of reduced load through the joint, a 2025 four-year cohort study of 1,153 participants offers a more specific answer. Weight loss above 5% significantly reduced the odds of higher-grade synovitis (OR 0.72; p=0.018), and that reduction in joint inflammation partially mediated slower cartilage degeneration at 48 months. The effect is not purely about kilograms on a set of scales: dampening chronic joint inflammation appears to be part of how weight loss protects the knee.

The risks of going too quickly deserve direct acknowledgement. Rapid weight loss in this population carries documented downsides — muscle loss (sarcopenia), reduced bone density, and joint instability — each of which can worsen the very problem a person is trying to address. High rates of weight regain are well documented when the approach is unsustainable, which means the goal is not an aggressive short-term target but a gradual, supervised reduction that can be maintained over time.

Used this way, weight loss is a structural element of the pre-replacement pathway — one that works alongside exercise rather than replacing it.

What injections offer — and where their limits lie

Injectable treatments occupy a distinct layer in the pathway: they address symptoms rather than the underlying disease, and none has been shown to slow structural progression or reduce the likelihood of eventually needing a replacement.

Corticosteroid injections sit earliest in the NHS sequence. They reduce joint inflammation and can meaningfully ease pain at an early-to-moderate stage — useful when flare-ups are limiting activity and other parts of the programme, such as exercise and weight management, still need time to take effect. Their role is symptomatic and bridging, not structural.

Hyaluronic acid injections aim to supplement synovial fluid viscosity. Their standing is contested: the OARSI guidelines assign them a weaker evidence rating than corticosteroids, and several meta-analyses have questioned whether their benefits meaningfully exceed those of placebo. They remain in clinical use, but patients should understand that the evidence base is genuinely uncertain.

Arthrosamid® — a polyacrylamide hydrogel — is used for adults with established knee OA and mild-to-moderate cartilage wear who prefer to avoid surgery. Injected under ultrasound guidance, it integrates with the synovial membrane and provides mechanical cushioning and lubrication. Clinical data suggest symptom improvements at around 27 weeks. It is worth being direct, though, about two things: the published evidence base for Arthrosamid® is smaller and less methodologically rigorous than the exercise data discussed earlier in this article, and the outcome figures reported in the literature do not yet carry the precision of the trial data cited above. More critically, Arthrosamid® does not regenerate cartilage, has not been shown to delay or prevent knee replacement, and is not appropriate for end-stage disease or significant joint deformity — clinical boundaries that matter when setting expectations.

Platelet-rich plasma (PRP) attracts growing interest, but evidence across trials remains inconsistent and current guidelines do not include it as a standard recommendation.

Joint-preserving surgery for the right active candidate

For active adults in their 50s and 60s who are not ready for joint replacement but have exhausted conservative options, surgery does not have to mean replacement. High tibial osteotomy (HTO) takes a different approach: rather than removing and replacing the joint surfaces, it realigns the leg to shift load away from the damaged compartment — typically the medial (inner) side — and onto healthier cartilage. The joint itself remains intact.

The conversion-to-replacement figures from a 2025 systematic review of 59 studies and 5,162 patients make the case plainly: only 4.5% of patients had converted to total knee replacement within five years, and 8.3% by the five-to-ten-year mark. For someone in their mid-50s, that represents a meaningful interval before a more definitive procedure becomes necessary, and one that can be spent maintaining function and activity.

The same patient profile that makes HTO appealing — active, motivated, unwilling to slow down — also shapes its outcomes. In a 2025 cohort study of young, active HTO patients, 86.7% returned to sport after the procedure. Notably, the factor that most reliably predicted failure to return was not age, BMI, or the type of sport: it was kinesiophobia — fear of movement — measured on a standardised scale (p=0.015). Psychological readiness, including confidence in loading the recovering joint, appears to matter as much as physical rehabilitation.

HTO suits a specific clinical profile: predominantly medial compartment OA, preserved cartilage in the lateral compartment, and no major joint deformity or instability. A thorough assessment, including imaging, is required to confirm suitability — it is not an option for all patients with knee OA, and end-stage disease or significant deformity would typically point towards a different pathway.

Building a staged plan: where to start and when to escalate

The stages described in this article are not alternatives to one another — they are layers. Exercise and weight management do not stop when injections are added; they remain the foundation throughout. An injection that reduces pain is most useful when it creates a window to exercise more effectively, not a reason to exercise less. Understanding this cumulative logic changes how the pathway feels: it is not a series of escalating defeats but a progressively tailored response to what the joint actually needs.

A common planning error is treating symptom severity as the only trigger for moving to the next stage. In practice, the decision involves imaging findings, overall function, personal goals, and — in the case of HTO — a specific anatomical profile. Two patients describing similar levels of daily discomfort may be in materially different positions if one has preserved cartilage on imaging and the other has confirmed structural decline.

The clearest signals that specialist input is warranted are practical rather than numerical: pain that continues to limit daily activity despite a properly supervised exercise programme; structural change confirmed on serial imaging; an inadequate or short-lived response to injections used appropriately. When these signals converge, a specialist assessment does not commit a patient to surgery — it establishes which options are realistic given their anatomy, activity levels, and goals.

A productive question to bring into that consultation is not 'do I need a replacement?' but 'which stage am I at, and what would it take to confirm readiness for the next one?'

If you are unsure where you sit in this pathway, a structured assessment is the most direct way to find out. Find out whether you're suitable →

1. [1] OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. (2019). https://doi.org/10.1016/j.joca.2019.06.011 https://doi.org/10.1016/j.joca.2019.06.011
2. [2] Comparison of weight loss interventions in overweight/obese adults with knee OA — systematic review and network meta-analysis. (2024). https://doi.org/10.1016/j.joca.2024.08.012 https://doi.org/10.1016/j.joca.2024.08.012
3. [3] Do we need another trial on exercise in patients with knee osteoarthritis? — No new trials on exercise in knee OA. (2019). https://doi.org/10.1016/j.joca.2019.04.020 https://doi.org/10.1016/j.joca.2019.04.020
4. [4] Mechanisms of action of therapeutic exercise for knee and hip OA remain a black box phenomenon — IPD mediation study, OA Trial Bank. (2023). https://doi.org/10.1136/rmdopen-2023-003220 https://doi.org/10.1136/rmdopen-2023-003220
5. [5] People with short symptom duration of knee OA benefit more from exercise therapy — IPD meta-analysis from the OA Trial Bank. (2024). https://doi.org/10.1016/j.joca.2024.07.007 https://doi.org/10.1016/j.joca.2024.07.007
6. [6] Synovitis mediates cartilage outcomes during weight-loss in knee OA — 4-year OAI follow-up. (2025). https://doi.org/10.1016/j.ocarto.2025.100653 https://doi.org/10.1016/j.ocarto.2025.100653
7. [7] Recent highlights and uncertainties in exercise management of knee osteoarthritis. (2025). https://doi.org/10.1016/j.jphys.2025.06.010 https://doi.org/10.1016/j.jphys.2025.06.010
8. [8] Conversion to Total Knee Arthroplasty After High Tibial Osteotomy — systematic review and meta-analysis. (2025). https://doi.org/10.1177/23259671241310963 https://doi.org/10.1177/23259671241310963
9. [9] Kinesiophobia and High-Impact Sport Activity Associated with Reduced Return to Sport After HTO. (2025). https://doi.org/10.1177/03635465251322795 https://doi.org/10.1177/03635465251322795